Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Crl
  6. /
  7. IBSA Institut Biochimique SA
CRL
•IBSA Institut Biochimique SA

IBSA Institut Biochimique SA – FDA CRL

Record Details

The FDA issued a Complete Response Letter (CRL) to Institut Biochimique SA (IBSA) regarding its New Drug Application (NDA 206976) for diclofenac epolamine topical system 1.3%, initially submitted on May 26, 2016. The application, filed under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, cannot be approved due to several deficiencies across clinical, nonclinical, and biopharmaceutical areas.A primary issue is the lack of sufficient data to bridge the product used in clinical studies with the product intended for commercialization, which is manufactured at a different site. IBSA must conduct a new, adequate, and well-controlled clinical efficacy and safety trial using the product from the proposed commercial manufacturing facility.Nonclinical concerns involve inadequate safety justification for unidentified leachable compounds exceeding the 5 mcg/day qualification threshold. IBSA needs to identify these compounds, provide a comprehensive toxicological risk assessment, or demonstrate their inability to penetrate the skin.The company's risk-based approach to support the manufacturing site change was deemed inadequate. Consequently, an in vivo bridging study—specifically, a new clinical efficacy and safety trial—is required, as per SUPAC-MR guidance, due to the unavailability of unexpired drug product from the original site for a direct pharmacokinetic comparison.Other required actions include demonstrating the discriminating ability of a specific quality control method, providing a comprehensive safety update, and submitting revised prescribing information in structured product labeling (SPL) format. The previously acceptable proprietary name, "Licart," also requires resubmission. This CRL necessitates significant additional data and studies to demonstrate the safety, effectiveness, and quality of the proposed drug product from the new manufacturing site.

Company
IBSA Institut Biochimique SA
Product type
Drugs
Office
Office of Drug Evaluation II
Person
  • Clarence E. Jones, PhD
View Company Profile

ID · d101ca50-a8f5-4485-a0a8-613fedc6f16a

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore IBSA Institut Biochimique SA
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.